106
Participants
Start Date
May 10, 2016
Primary Completion Date
September 10, 2018
Study Completion Date
December 21, 2018
SRX246
Placebo
Columbia University Medical Center, New York Presbyterian Hospital, New York
SUNY Stony Brook Clinical Research Center, Department of Neurology, East Setauket
University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center, Department of Neurology, Pittsburgh
University of Virginia Health System, Department of Neurology, Charlottesville
Emory University, Atlanta
University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital, Miami
University of Alabama, Birmingham
Vanderbilt Clinical Research Center, Nashville
Ohio State University, Wexner Medical Center, Department of Neurology, Columbus
University Medical Arts Building, Cincinnati
Northwestern Out-Patient Neurology Clinic, Chicago
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Kansas City
UT Southwestern Medical Center, Dallas
University of Colorado Hospital Translational Research Center, Aurora
University of Utah, Department of Neurology, Salt Lake City
UCLA, Neurology Clinic, Los Angeles
UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center, Sacramento
Oregon Health and Science University, Portland
Swedish Neuroscience Institute, Seattle
Massachusetts General Hospital, Charlestown
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
NeuroNEXT Network
OTHER
Azevan Pharmaceuticals
INDUSTRY